VALBIOTIS: Euroland Corporate initiates coverage of the stock

VALBIOTIS, a French laboratory specializing in food supplements, announces that Euroland Corporate has initiated coverage of its stock. This decision is accompanied by a study entitled "Nutraceuticals for Cardio-Metabolic Health," which recommends buying the stock with a target price of €2.16. This figure represents a potential upside of 163% compared to the closing price on January 27, 2025.

Euroland Corporate has joined Invest Securities and TP ICAP Midcap in covering Valbiotis shares. The full report is available on the Valbiotis website, under the Investors section. This move reinforces the analysts' consensus on the company's valuation.